News

Pending a safety investigation by the developer and further information about risk to patients, the phase 1b trial of CYAD-101 in patients with metastatic colorectal cancer, has been placed on a partial clinical hold by the FDA.

In patients with early stage glottic larynx tumor-focused stereotactic radiotherapy showed benefit in a phase 2 study.

AON will provide ambulatory infusion pumps and services, effective January 1, 2022 in partnership with InfuSystem.

Here's a look back at all the FDA happenings from February 2022.

Results from the WINDOW-1 signal promise for use of the R-HCVAD regimen in patients with mantle cell lymphoma.

The FDA has approved pacritinib for the treatment of patients with myelofibrosis and severe thrombocytopenia.

Ciltacabtagene autoleucel had been granted FDA approval for the treatment of select patients with relapsed or refractory multiple myeloma.

In an interview with Targeted Oncology, Sophia Kamran, MD, discussed the effectiveness of trimodality therapy as well as other novel therapeutics in patients with bladder cancer.

The supplemental new drug application for ibrutinib as a potential treatment for pediatric chronic graft-versus-host disease is supported with findings from the phase 1/2 IMAGINE study.

The FDA will conduct a speedy review of the supplemental biologics license application filed for nivolumab in combination with chemotherapy and granted it priority review for the neoadjuvant treatment of patients with resectable non–small cell lung cancer.

The treatment and preventive agent landscape for graft-versus-host disease is growing for patients with hematologic malignancies who receive a stem cell transplant.

Findings from the MC1273 and MC1675 trials show that de-escalated adjuvant radiation therapy met criteria for efficacy in human papillomavirus–related oropharyngeal squamous cell carcinoma.

Thomas Marron, PhD, MD, discusses the end points of an exploratory study which examines the use of cemiplimab in hepatocellular carcinoma.

Regarding cutaneous squamous cell carcinoma, what is most exciting is the remarkable complete response rate, up to almost 50%, according Jiaxin Niu, MD.

New data show that de-escalated radiotherapy dose to 54 Gy vs 70 Gy may achieve better measures of toxicity in patients with p16-positive oropharyngeal squamous cell carcinoma.

Overall survival was prolonged with the addition of darolutamide to androgen-deprivation therapy and docetaxel in patient with metastatic, hormone-sensitive prostate cancer.

The phase 2/3 RINGSIDE clinical trial of AL102 has reached a key enrollment milestone.

The MARIPOSA study seeks to assess efficacy, safety, and pharmacokinetics of the combination of amivantamab-vmjw and lazertinib in locally advanced, or metastatic non-small cell lung cancer.

In an interview with Targeted Oncology, Annelise Wilhite, MD, discussed the findings of a clinical investigation of survival in patients with vulvar/vaginal melanomas.

Thomas Habermann, MD, discusses R-CHOP and how it can be improved upon as a treatment method for diffuse large B-cell lymphoma.

A reduction in cabozantinib dosage because of toxicity shows improved time to treatment failure and overall survival in patients with metastatic renal cell carcinoma.

The collaboration between AON and VieCure is designed to facilitate the delivery of precision oncology and personalized care and treatment for patients across the ever-expanding AON network.

Data supporting zanubrutinib for the treatment of chronic lymphocytic leukemia or small lymphocytic leukemia will undergo a regular FDA review in consideration for FDA approval.

The FDA has approved FoundationOne CDx as a companion diagnostic to pembrolizumab for patients with microsatellite instability high solid tumors.

Richard Silver, MD, discusses the Interferon Initiative organized by the Myeloproliferative Neoplasm Research Foundation.

Significant survival improvement has been shown with trastuzumab deruxtecan in patients with HER2-low breast cancer treated in the DESTINY-Breast04 clinical trial.

In an interview with Targeted Oncology, Tanios S. Bekaii-Saab, MD, explained how adagrasib works to target KRAS mutations as well as its importance.

Vivek Subbiah discusses the phase 1/2 LIBRETTO-001 study which sought to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of selpercatinib in patients with advanced solid tumors.

BOS172738 shows promising results in the treatment of RET gene altered medullary thyroid cancer and non–small cell lung cancer, according to a phase 1 study.

In an interview with Targeted Oncology, Vitaly Margulis, MD, discussed the function and findings of metabolomics in renal cell carcinoma.